SCHEMBL20119586

SCHEMBL20119586

Clc1nc(NCc2ccco2)c2[nH]ccc2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.65
KMT2A Q03164 8/20 0.48
HTT P42858 4/20 0.47
LMNA P02545 4/20 0.47
MEN1 O00255 5/20 0.47
HSD17B10 Q99714 2/20 0.47
PKM P14618 1/20 0.47
MAPT P10636 5/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPK1 P28482 2/20 0.47
BLM P54132 1/20 0.47
HIF1A Q16665 2/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
KDR P35968 1/20 0.46
RECQL P46063 1/20 0.44
PDE5A O76074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31745029 0.81 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL20119352 0.81 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL20119690 0.79 SMN1; SMN2 (0.64) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL22754157 0.79 JAK2 (0.46) SMN1; SMN2HSD17B10PDE5AEGFR
SCHEMBL2833837 0.79 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL30455170 0.77 PDE5A (0.70) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL21460561 0.77 PDE5A (0.70) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL20119882 0.74 SMN1; SMN2 (0.58) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL13087414 0.74 SMN1; SMN2 (0.68) SMN1; SMN2KMT2AHTTLMNAMEN1
SCHEMBL23498540 0.74 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AHTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023338-B2 Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities KYOTO UNIVERSITY (JP) 2024-07-02 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20210205314-A1 PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES KYOTO UNIVERSITY (JP) 2021-07-08 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HTT 326/4885
US-20210205314-A1 PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES RBM17, SFPQ, HNRNPAB SMN1; SMN2 37/4885KMT2A 3468/4885HTT 114/4885
US-12023338-B2 Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities RBM17, SFPQ, HNRNPAB SMN1; SMN2 37/4885KMT2A 3468/4885HTT 114/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HTT 326/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HTT 326/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HTT 326/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885HTT 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.